U.S. flag

An official website of the United States government

NIH: Fogarty International Center NIH: Fogarty International Center
Advancing Science for Global Health
Advancing Science for Global Health
Home > Grants > Search Current & Recent Grants > Dolutegravir for the Treatment of HIV in Patients with Tuberculosis in Kwazulu-Natal South Africa Print

Dolutegravir for the Treatment of HIV in Patients with Tuberculosis in Kwazulu-Natal South Africa

The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).

Funding Fogarty Program

Emerging Global Leader

Project Information in NIH RePORTER

Dolutegravir for the Treatment of HIV in Patients with Tuberculosis in Kwazulu-Natal South Africa

Principal Institution

Center for the AIDS Program of Research in South Africa (CAPRISA)

Principal Investigator(s) (PI)

Naidoo, Anushka

Project Contact Information

Email: anushka.naidoo@caprisa.org

Year(s) Awarded

2019-2024

Country

South Africa

Collaborators

Johns Hopkins University

Project Description

The World Health Organization recommends the antiretroviral drug dolutegravir as first-line treatment of HIV. However there is some uncertainty regarding its optimal use in  patients with HIV-TB co-infection who are taking tuberculosis (TB) drugs due to some drug-drug interactions that may reduce dolutegravir efficacy. This study aims to fill this knowledge gap by understanding the impact of drug interactions with TB drugs on dolutegravir drug concentrations, adherence, and treatment outcomes. The study will be conducted in a high HIV-TB burden setting in KwaZulu-Natal South Africa.

Related World Regions / Countries

Related Global Health Research Topics